Certara

Certara

Biosimulation and data science solutions provider

About Certara

Simplify's Rating
Why Certara is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

AI & Machine Learning

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Princeton, New Jersey

Founded

2008

Overview

Certara provides biosimulation and data science solutions to enhance drug development and regulatory submissions. Their products include software and consulting services that help pharmaceutical and biotechnology companies, as well as regulatory agencies, make better decisions throughout the drug development process. Certara's software allows users to simulate biological processes and visualize data, which aids in improving the efficiency and success rates of clinical trials. Unlike many competitors, Certara combines advanced technologies like deep learning and artificial intelligence in their offerings. The company's goal is to optimize the drug development lifecycle, making it more effective and successful.

Simplify Jobs

Simplify's Take

What believers are saying

  • Certara's acquisition of Chemaxon enhances its drug discovery software portfolio.
  • The biosimulation market is projected to grow significantly, benefiting Certara.
  • Certara's CoAuthor platform streamlines medical writing, improving efficiency.

What critics are saying

  • Increased competition could erode Certara's market share.
  • Rapid technological advancements may outpace Certara's current capabilities.
  • Regulatory scrutiny on AI tools could delay Certara's product approvals.

What makes Certara unique

  • Certara offers a unique combination of biosimulation and data science solutions.
  • The company leverages AI to enhance drug development and regulatory submissions.
  • Certara's Phoenix software is a gold standard in pharmacokinetic modeling.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$2106.5M

Above

Industry Average

Funded Over

4 Rounds

Secondary funding comparison data is currently unavailable. We're working to provide this information soon!
Secondary Funding Comparison
Coming Soon

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

-3%
Stock Titan
Mar 5th, 2025
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions

Certara (NASDAQ: CERT) has appointed Dr. Adrian McKemey as President of Drug Development Solutions, effective March 3rd, 2025.

Hit Consultant
Jan 17th, 2025
Recent Digital Health Executive Hires And Promotions: Medidata Expands Team, Carerev, Philips, Eko Health, Others

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

PharmiWeb
Oct 18th, 2024
Biosimulation Market to Grow at a CAGR of 21.5% During the Ensuing Ten years, Reaching USD 20.9 Billion by the end of 2032.

In June 2022, Certara announced its new version of Biosimulation software for the progress of Novel Biologics.

Certara
Oct 16th, 2024
Certara Appoints John Reynders as New Independent Board Member

Certara appoints John Reynders as new independent board member.

GlobeNewswire
Aug 15th, 2024
Certara Launches Phoenix(Tm) Version 8.5 Drug Development Software

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry's gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S

Recently Posted Jobs

Sign up to get curated job recommendations

Certara is Hiring for 30 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Certara's jobs every few hours, so check again soon! Browse all jobs →